Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis

International Immunopharmacology

Volumn 5, Issue 3, 2005, Pages 591-599

  Hwang, Shen An ^a   Kruzel, Marian L ^a   Actor, Jeffrey K ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

BCG vaccine efficacy; Lactoferrin; Mycobacterium tuberculosis

Indexed keywords

BCG VACCINE; FREUND ADJUVANT; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTOFERRIN; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BCG VACCINATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; IMMUNOPHARMACOLOGY; IMMUNOREGULATION; IMMUNOSTIMULATION; INFECTION PREVENTION; LUNG; MACROPHAGE ACTIVATION; MEDIATOR; MEDIATOR RELEASE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUBERCULOSIS;

EID: 15944378224     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2004.11.006     Document Type: Article

References (29)

1. World Health Organization Global tuberculosis control. Surveillance, planning, financing The world health report 2003 2003 World Health Organization Geneva (Switzerland)
2. J.L. Flynn Immunology of tuberculosis and implications in vaccine development Tuberculosis (Edinb.) 84 2004 93
3. B.R. Bloom, J. Flynn, K. McDonough, Y. Kress, and J. Chan Experimental approaches to mechanisms of protection and pathogenesis in M. tuberculosis infection Immunobiology 191 1994 526
4. M. Brennan A new generation of tuberculosis vaccine C.A. de Quadros Vaccines: preventing disease & preventing health 2004 Pan American Health Organization Washington (DC) 177
5. M. Zimecki, J. Artym, G. Chodaczek, M. Kocieba, and M.L. Kruzel Protective effects of lactoferrin in Escherichia coli-induced bacteremia in mice: relationship to reduced serum TNF alpha level and increased turnover of neutrophils Inflamm. Res. 53 2004 292
6. D. Legrand, E. Elass, A. Pierce, and J. Mazurier Lactoferrin and host defense: an overview of its immuno-modulating and anti-inflammatory properties Biometals 17 2004 225
7. M.L. Kruzel, Y. Harari, D. Mailman, J.K. Actor, and M. Zimecki Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice Clin. Exp. Immunol. 130 2002 25
8. B. Adamik, M. Zimecki, A. Wlaszczyk, P. Berezowicz, and A. Kubler Lactoferrin effects on the in vitro immune response in critically ill patients Arch. Immunol. Ther. Exp. (Warsz.) 46 1998 169
9. Y.A. Suzuki, and B. Lonnerdal Characterization of mammalian receptors for lactoferrin Biochem. Cell. Biol. 80 2002 75
10. M.L. Kruzel, and M. Zimecki Lactoferrin and immunologic dissonance: clinical implications Arch. Immunol. Ther. Exp. (Warsz.) 50 2002 399
11. M. Zimecki, and M.L. Kruzel Systemic or local co-administration of lactoferrin with sensitizing dose of antigen enhances delayed type hypersensitivity in mice Immunol. Lett. 74 2000 183
12. J.K. Actor, S.A. Hwang, M. Olsen, M. Zimecki, R.L. Hunter Jr., and M.L. Kruzel Lactoferrin immunomodulation of DTH response in mice Int. Immunopharmacol. 2 2002 475
13. J.K. Actor, E. Breij, R.A. Wetsel, H. Hoffmann, R.L. Hunter Jr., and C. Jagannath A role for complement C5 in organism containment and granulomatous response during murine tuberculosis Scand. J. Immunol. 53 2001 464
14. D.M. Lewinsohn, D.A. Lewinsohn, and J.E. Grotzke TB vaccines at the turn of the century: insights into immunity to M. tuberculosis and modern approaches for prevention of an ancient disease Semin. Respir. Infect. 18 2003 320
15. T. Lietman, and S.M. Blower Potential impact of tuberculosis vaccines as epidemic control agents Clin. Infect. Dis. 30 Suppl. 3 2000 S316
16. C.J. Murray, and J.A. Salomon Modeling the impact of global tuberculosis control strategies Proc. Natl. Acad. Sci. U. S. A. 95 1998 13881
17. C. Manca, L. Tsenova, A. Bergtold, S. Freeman, M. Tovey, and J.M. Musser Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/beta Proc. Natl. Acad. Sci. U. S. A. 98 2001 5752
18. G.A. Colditz, T.F. Brewer, C.S. Berkey, M.E. Wilson, E. Burdick, and H.V. Fineberg Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature JAMA 271 1994 698
19. S.P. Crouch, K.J. Slater, and J. Fletcher Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin Blood 80 1992 235
20. E. Elass-Rochard, D. Legrand, V. Salmon, A. Roseanu, M. Trif, and P.S. Tobias Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein Infect. Immun. 66 1998 486
21. K. Miyazawa, C. Mantel, L. Lu, D.C. Morrison, and H.E. Broxmeyer Lactoferrin-lipopolysaccharide interactions. Effect on lactoferrin binding to monocyte/macrophage-differentiated HL-60 cells J. Immunol. 146 1991 723
22. A.M. Cooper, A. Kipnis, J. Turner, J. Magram, J. Ferrante, and I.M. Orme Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present J. Immunol. 168 2002 1322
23. A.M. Cooper, J. Magram, J. Ferrante, and I.M. Orme Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis J. Exp. Med. 186 1997 39
24. D.N. McMurray Recent progress in the development and testing of vaccines against human tuberculosis Int. J. Parasitol. 33 2003 547
25. N.M. Nor, and M. Musa Approaches towards the development of a vaccine against tuberculosis: recombinant BCG and DNA vaccine Tuberculosis (Edinb.) 84 2004 102
26. J. Wang, and Z. Xing Tuberculosis vaccines: the past, present and future Expert. Rev. Vaccines 1 2002 341
27. H. Kumar, D. Malhotra, S. Goswami, and R.N. Bamezai How far have we reached in tuberculosis vaccine development? Crit. Rev. Microbiol. 29 2003 297
28. D.M. Collins New tuberculosis vaccines based on attenuated strains of the Mycobacterium tuberculosis complex Immunol. Cell Biol. 78 2000 342
29. H.L. Collins, and S.H. Kaufmann Prospects for better tuberculosis vaccines Lancet, Infect. Dis. 1 2001 21